Display options
Cite
Wangnoo SK, Kumar S, Bhattacharyya A, et al. Liraglutide effect and action in diabetes-In (LEAD-In): A prospective observational study assessing safety and effectiveness of liraglutide in patients with type 2 diabetes mellitus treated under routine clinical practice conditions in India. Indian J Endocrinol Metab. 2016;20(6):838-845doi: 10.4103/2230-8210.189232.
Wangnoo, S. K., Kumar, S., Bhattacharyya, A., Tripathi, S., Akhtar, S., Shetty, R., & Ghosal, S. (2016). Liraglutide effect and action in diabetes-In (LEAD-In): A prospective observational study assessing safety and effectiveness of liraglutide in patients with type 2 diabetes mellitus treated under routine clinical practice conditions in India. Indian journal of endocrinology and metabolism, 20(6), 838-845. https://doi.org/10.4103/2230-8210.189232
Wangnoo, Subhash Kumar, et al. "Liraglutide effect and action in diabetes-In (LEAD-In): A prospective observational study assessing safety and effectiveness of liraglutide in patients with type 2 diabetes mellitus treated under routine clinical practice conditions in India." Indian journal of endocrinology and metabolism vol. 20,6 (2016): 838-845. doi: https://doi.org/10.4103/2230-8210.189232
Wangnoo SK, Kumar S, Bhattacharyya A, Tripathi S, Akhtar S, Shetty R, Ghosal S. Liraglutide effect and action in diabetes-In (LEAD-In): A prospective observational study assessing safety and effectiveness of liraglutide in patients with type 2 diabetes mellitus treated under routine clinical practice conditions in India. Indian J Endocrinol Metab. 2016 Nov-Dec;20(6):838-845. doi: 10.4103/2230-8210.189232. PMID: 27867889; PMCID: PMC5105570.
Copy Download .nbib Format: NLM
Share it on

Indian J Endocrinol Metab. 2016 Nov-Dec;20(6):838-845. doi: 10.4103/2230-8210.189232.

Liraglutide effect and action in diabetes-In (LEAD-In): A prospective observational study assessing safety and effectiveness of liraglutide in patients with type 2 diabetes mellitus treated under routine clinical practice conditions in India.

Indian journal of endocrinology and metabolism

Subhash Kumar Wangnoo, Surender Kumar, Arpandev Bhattacharyya, Sudhir Tripathi, Shahid Akhtar, Raman Shetty, Samit Ghosal

Affiliations

  1. Apollo Centre of Obesity, Diabetes and Endocrinology, Indraprastha Apollo Hospital, New Delhi, India.
  2. Department of Endocrinology and Metabolism, Sir Ganga Ram Hospital, New Delhi, India.
  3. Department of Endocrinology, Manipal Hospital, Bengaluru, Karnataka, India.
  4. Clinical, Medical and Regulatory Department, Novo Nordisk Pharma Gulf FZ-LLC, Dubai, United Arab Emirates.
  5. Department of Diabetology, Nightingale Hospital, Kolkata, West Bengal, India.

PMID: 27867889 PMCID: PMC5105570 DOI: 10.4103/2230-8210.189232

Abstract

BACKGROUND: This 26-week, open-label observational study assessed the incidence and type of adverse events (AEs) associated with liraglutide use according to the standard clinical practice settings and the local label in India.

MATERIALS AND METHODS: A total of 1416 adults with type 2 diabetes (T2D) treated with liraglutide in 125 sites across India were included in the study. Participants were newly diagnosed or already receiving antidiabetic medications. Safety and efficacy data were collected at baseline and at approximately weeks 13 and 26. The primary outcome was incidence and type of AEs while using liraglutide, with events classified by Medical Dictionary for Regulatory Activities system organ class and preferred term. The secondary objective was to assess other clinical parameters related to effective T2D management.

RESULTS: Twenty AEs, predominately gastrointestinal, were reported in 1.3% of the study population in scheduled visits up to week 26. No serious AEs, including death, were reported. Hypoglycemic episodes were reported in 7.3% of participants at baseline and 0.7% at week 26. No major hypoglycemic events were reported up to week 26 (baseline: 0.4%). Glycated hemoglobin was reduced from baseline (8.8 ± 1.3%) to week 26 by 1.6 ± 1.1% (

CONCLUSIONS: From the number of AEs reported, it is suggested that liraglutide was well tolerated in subjects with T2D treated under standard clinical practice conditions in India. Liraglutide was effective, and no new safety concerns were identified.

Keywords: Adverse events; India; liraglutide; real-world; routine clinical practice; type 2 diabetes

References

  1. Diabetes Care. 2015 Jan;38(1):140-9 - PubMed
  2. Diabetologia. 2008 Jan;51(1):91-100 - PubMed
  3. JAMA. 1997 Mar 19;277(11):925-6 - PubMed
  4. Diabetes Care. 2014 Jan;37 Suppl 1:S5-13 - PubMed
  5. Am J Physiol Endocrinol Metab. 2008 Nov;295(5):E1160-6 - PubMed
  6. N Engl J Med. 2014 Feb 27;370(9):794-7 - PubMed
  7. Lancet. 2009 Jul 4;374(9683):39-47 - PubMed
  8. Diabet Med. 2013 Mar;30(3):300-8 - PubMed
  9. Cell Res. 2005 Jan;15(1):72-7 - PubMed
  10. Cardiovasc Diabetol. 2012 Nov 15;11:142 - PubMed
  11. Diabetes Care. 2009 Jan;32(1):84-90 - PubMed
  12. Diabetologia. 2009 Oct;52(10):2046-55 - PubMed
  13. Diabetes Ther. 2013 Jun;4(1):147-51 - PubMed
  14. N Engl J Med. 2008 May 1;358(18):1969-70; discussion 1971-2 - PubMed
  15. Diabetes Care. 2015 Jun;38(6):1058-66 - PubMed
  16. Pharm Pract (Granada). 2012 Oct;10(4):222-6 - PubMed
  17. Lancet. 2009 Feb 7;373(9662):473-81 - PubMed
  18. Indian J Endocrinol Metab. 2014 Jan;18(1):77-82 - PubMed
  19. Diabetes Care. 2006 Feb;29(2):471 - PubMed
  20. Diabet Med. 2009 Mar;26(3):268-78 - PubMed
  21. Int J Clin Pract. 2011 Apr;65(4):397-407 - PubMed
  22. Diabetes Care. 2009 Jul;32(7):1224-30 - PubMed

Publication Types